AU774278B2 - Pharmaceutical formulation comprising omeprazole - Google Patents

Pharmaceutical formulation comprising omeprazole Download PDF

Info

Publication number
AU774278B2
AU774278B2 AU14346/00A AU1434600A AU774278B2 AU 774278 B2 AU774278 B2 AU 774278B2 AU 14346/00 A AU14346/00 A AU 14346/00A AU 1434600 A AU1434600 A AU 1434600A AU 774278 B2 AU774278 B2 AU 774278B2
Authority
AU
Australia
Prior art keywords
omeprazole
hpc
cloud point
active ingredient
core material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU14346/00A
Other languages
English (en)
Other versions
AU1434600A (en
Inventor
Pontus Bergstrand
Peter Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20413180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU774278(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU1434600A publication Critical patent/AU1434600A/en
Application granted granted Critical
Publication of AU774278B2 publication Critical patent/AU774278B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU14346/00A 1998-11-05 1999-11-03 Pharmaceutical formulation comprising omeprazole Ceased AU774278B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9803772A SE9803772D0 (sv) 1998-11-05 1998-11-05 Pharmaceutical formulation
SE9803772 1998-11-05
PCT/SE1999/001989 WO2000027366A1 (en) 1998-11-05 1999-11-03 Pharmaceutical formulation comprising omeprazole

Publications (2)

Publication Number Publication Date
AU1434600A AU1434600A (en) 2000-05-29
AU774278B2 true AU774278B2 (en) 2004-06-24

Family

ID=20413180

Family Applications (1)

Application Number Title Priority Date Filing Date
AU14346/00A Ceased AU774278B2 (en) 1998-11-05 1999-11-03 Pharmaceutical formulation comprising omeprazole

Country Status (20)

Country Link
US (1) US6428810B1 (es)
EP (1) EP1124539B1 (es)
JP (2) JP5412021B2 (es)
KR (1) KR100627205B1 (es)
CN (1) CN1160062C (es)
AT (1) ATE244002T1 (es)
AU (1) AU774278B2 (es)
BR (1) BR9915087A (es)
CA (1) CA2346988C (es)
DE (1) DE69909316T2 (es)
DK (1) DK1124539T3 (es)
ES (1) ES2201837T3 (es)
HK (1) HK1039070B (es)
IL (2) IL142474A0 (es)
NO (1) NO320056B1 (es)
NZ (1) NZ510993A (es)
PT (1) PT1124539E (es)
SE (1) SE9803772D0 (es)
WO (1) WO2000027366A1 (es)
ZA (1) ZA200103336B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
TWI232761B (en) * 2000-07-01 2005-05-21 Pharmaceutical Ind Tech & Dev Capsule preparation for oral administration and the preparation method thereof
US6418968B1 (en) 2001-04-20 2002-07-16 Nanostream, Inc. Porous microfluidic valves
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
ATE376826T1 (de) 2001-09-28 2007-11-15 Mcneil Ppc Inc Darreichungsformen zur modifizierten freisetzung
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
WO2003049693A2 (en) * 2001-12-06 2003-06-19 Wyeth Method and composition for inducing weight loss
US6982080B2 (en) * 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
US20040126358A1 (en) * 2002-09-16 2004-07-01 Warne Nicholas W. Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same
AU2003900096A0 (en) * 2003-01-10 2003-02-20 Nature Vet Orally deliverable pharmaceutical composition protein pump inhibitors
US20040185119A1 (en) * 2003-02-26 2004-09-23 Theuer Richard C. Method and compositions for treating gastric hyperacidity while diminishing the likelihood of producing vitamin deficiency
WO2004089333A2 (en) * 2003-02-28 2004-10-21 Cadila Healthcare Limited A stable benzimidazole formulation
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
CN1938026A (zh) * 2004-03-26 2007-03-28 卫材R&D管理有限公司 控释制剂及其制造方法
JP2007532677A (ja) * 2004-04-16 2007-11-15 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤、および運動促進薬の組み合わせ
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US20090148519A1 (en) * 2005-09-29 2009-06-11 Yasuhiro Zaima Pulsed-release preparation having improved disintegration properties in vivo
CN101309917B (zh) * 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
CN100431526C (zh) * 2005-11-07 2008-11-12 上海艾力斯医药科技有限公司 一种酸敏感型药物的快速崩解片剂
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
US20100297226A1 (en) * 2006-06-01 2010-11-25 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
EP2068841B1 (en) 2006-10-05 2018-09-26 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20100105738A1 (en) * 2006-10-06 2010-04-29 Mitsuru Mizuno Extended release formulations of a proton pump inhibitor
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
AU2008304033B2 (en) * 2007-09-28 2014-05-01 Ctc Bio, Inc. Pharmaceutical composition containing esomeprazole
US20090280175A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Proton Pump Inhibitor Tablets
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
KR20110079641A (ko) 2008-09-09 2011-07-07 아스트라제네카 아베 제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법
EA021112B1 (ru) * 2009-06-25 2015-04-30 Поузен Инк. Способ лечения боли и/или воспаления у пациента, нуждающегося в аспириновой терапии
SG176724A1 (en) 2009-06-25 2012-01-30 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CN102631327B (zh) * 2012-05-14 2013-08-28 海南葫芦娃制药有限公司 一种奥美拉唑肠溶微丸及其制备方法
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
JP6967513B2 (ja) * 2015-12-22 2021-11-17 シエル・インターナシヨナル・リサーチ・マートスハツペイ・ベー・ヴエー 溶融ポリカーボネートを生成するための方法
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0496437A2 (en) * 1986-04-30 1992-07-29 Aktiebolaget Hässle Use of specific core material and layers to obtain pharmaceutical formulations stable to discolouration of omeprazole
WO1997025066A1 (en) * 1996-01-08 1997-07-17 Astra Aktiebolag Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
CN1138534C (zh) 1994-07-08 2004-02-18 阿斯特拉曾尼卡有限公司 多单元片剂
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0496437A2 (en) * 1986-04-30 1992-07-29 Aktiebolaget Hässle Use of specific core material and layers to obtain pharmaceutical formulations stable to discolouration of omeprazole
WO1997025066A1 (en) * 1996-01-08 1997-07-17 Astra Aktiebolag Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate

Also Published As

Publication number Publication date
HK1039070A1 (en) 2002-04-12
CA2346988C (en) 2009-02-10
AU1434600A (en) 2000-05-29
EP1124539B1 (en) 2003-07-02
NO20012222D0 (no) 2001-05-04
JP2002529397A (ja) 2002-09-10
ATE244002T1 (de) 2003-07-15
ES2201837T3 (es) 2004-03-16
PT1124539E (pt) 2003-11-28
NZ510993A (en) 2003-08-29
KR100627205B1 (ko) 2006-09-22
CA2346988A1 (en) 2000-05-18
DE69909316T2 (de) 2004-06-03
DK1124539T3 (da) 2003-10-06
DE69909316D1 (de) 2003-08-07
EP1124539A1 (en) 2001-08-22
KR20010075685A (ko) 2001-08-09
IL142474A0 (en) 2002-03-10
NO320056B1 (no) 2005-10-17
HK1039070B (zh) 2003-12-19
JP5412021B2 (ja) 2014-02-12
BR9915087A (pt) 2001-07-17
SE9803772D0 (sv) 1998-11-05
ZA200103336B (en) 2002-07-24
JP2012031189A (ja) 2012-02-16
WO2000027366A1 (en) 2000-05-18
NO20012222L (no) 2001-07-02
US6428810B1 (en) 2002-08-06
CN1325300A (zh) 2001-12-05
CN1160062C (zh) 2004-08-04
IL142474A (en) 2007-08-19

Similar Documents

Publication Publication Date Title
AU774278B2 (en) Pharmaceutical formulation comprising omeprazole
CA2290531C (en) Pharmaceutical formulation of omeprazole
KR100384961B1 (ko) 프로톤펌프억제제를함유하는다단위제약제제
EP0814783B1 (en) Multiple unit effervescent dosage forms comprising protonpump inhibitor
EP0502556B1 (en) Use of specific core material and layers to obtain pharmaceutical formulations stable to discolouration of acid labile compounds
KR100384960B1 (ko) 다단위정제투여형i
KR100717661B1 (ko) 신규 제형
SA97170553B1 (ar) اشكال معايرة جرعات صيدلانية تعطى بالفم تتضمن مثبط مضخة البروتون proton pump inhibitor وعامل مضاد للحموضة او الجينات alginate
AU5791900A (en) Solid oral pharmaceutical formulation of modified release that contains an acid labile benzimidazole compound
MX2012005341A (es) Forma de dosificacion solida farmaceutica.
MXPA99010910A (es) Formulacion farmaceutica de omeprazol

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)